Delving into the Latest Updates on Shenzhen Wingor Bio-technology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Shenzhen Wingor Bio-technology Co., Ltd. is a company that specializes in the R&D and manufacturing of anti-tumor biological immune cell products. The firm provides a variety of solutions including chimeric antigen receptor T lymphocyte, clustered regulatory interspaced short palindromic repeat, mesenchymal stem cell, methyl triazeno imidazole carboxamide technology, and cryobiomedical technology. Established on March 12, 2013, the company's headquarters are located in Shenzhen, China.

Tags

Neoplasms

Immune System Diseases

Respiratory Diseases

Stem cell therapy

Gene editing

CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	14
Immune System Diseases	11
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Infectious Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Stem cell therapy	8
CAR-T	3
Gene editing	3
Exosomes	1
Fusion protein	1

Top 5 Target	Count

GLP-1 x PTGFRN	1

This study is a randomized double-blind placebo-controlled multicenter clinical trial to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell (UC-MSC) transplantation for the treatment of acute-on-chronic liver failure (ACLF). UC-MSC therapy may improve the clinical outcomes of patients with ACLF. The trial would provide scientific evidence for UC-MSC transplantation as a potential treatment for ACLF.

Start Date30 Sep 2023

Sponsor / Collaborator

302 Military Hospital of China

[+2]

100 Clinical Results associated with Shenzhen Wingor Bio-technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shenzhen Wingor Bio-technology Co., Ltd.

Login to view more data

2

Literatures (Medical) associated with Shenzhen Wingor Bio-technology Co., Ltd.

01 Nov 2020·Molecular Human ReproductionQ3 · MEDICINE

Annexin A2 acts as an adherent molecule under the regulation of steroids during embryo implantation

Q3 · MEDICINE

Article

Author: Shao, Yan ; Wang, Bing

AbstractWe previously showed that annexin A2 (Axna2) was transiently expressed at the embryo-uterine luminal epithelium interface during the window of implantation and was involved in mouse embryo implantation. At the same time, Axna2 was reported to be upregulated in human receptive endometrium, which was critical for embryo attachment as an intracellular molecule. Here, we identified Axna2 as a membrane-bound molecule on human endometrial epithelial cells and trophoblast cells, and the outer surface membrane-bound Axna2 was involved in human embryo attachment. In addition, physiological levels of estrogen and progesterone increased the expression of overall Axna2 as well as that in the extracellular surface membrane protein fraction in human endometrial cells. Furthermore, p11 (or S100A10, a member of the S100 EF-hand family protein, molecular weight 11 kDa) was involved in the translocation of Axna2 to the outer surface membrane of endometrial epithelial cells without affecting its overall expression. Finally, the surface relocation of Axna2 was also dependent on cell–cell contact and calcium binding. A better understanding of the function and regulation of Axna2 in human endometrium may help us to identify a potential therapeutic target for subfertile and infertile patients.

Zhongguo Linchuang Yaolixue Zazhi

Lead tolerance of metallothionein-overexpressed human adipose-derived mesenchymal stem cells

Author: Xie, Liang ; Luo, Zhao-xia ; Jiang, Shu ; Yang, Shun ; Liu, Xiao-lei ; Zhang, Yun ; Ji, Xi-luan ; Li, Jie-ming

Objective The lentiviral vector was recombined with metallothionein (MT) gene to identify the MT overexpression in human adipose-derived mesenchymal stem cells (hADSCs) after transfection and then to study the lead tolerance of genetically modified hADSCs with MT (MT-hADSCs).Methods The recombinant pLenti-CMV-MT2A-EYFP vector was constructed with pLenti-CMV-hChR 2 (E123T-H134R)-EYFP and MT2A gene for transfecting hADSCs to obtain the MT-hADSCs.The overexpression of MT in hADSCs was identified by immunofluorescence assay.The MTT method was used to assess the cell viability of hADSCs, hADSCs transfected with empty vector, and MT-hADSCs, all of which were treated with lead acetate.Results The recombinant pLenti-CMV-MT2A-EYFP was successfully constructed and transfected into hADSCs.The overexpression of MT was pos. detected in the MT-hADSCs.The tolerance of MT-hADSCs to lead was significantly higher than the hADSCs and hADSCs transfected with empty vector.Conclusion MT could significantly increase the tolerance of hADSCs to lead, indicating that MT could reduce the cytotoxicity of lead.The exptl. results from this study provided more evidences for further study of using MT-hADSCs to treat lead poisoning.

100 Deals associated with Shenzhen Wingor Bio-technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shenzhen Wingor Bio-technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

7

8

Preclinical

Phase 1 Clinical

1

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Human cord derived MSC cell (Shenzhen Wingor Bio-technology)	Acute-On-Chronic Liver Failure More	Phase 2 Clinical
WG-103	Neoplasms More	Phase 1
WG-101	Hematologic Neoplasms More	Preclinical
WG-108	Immune System Diseases More	Preclinical
WG-105	Neoplasms More	Preclinical